3D Mol Similar

Baclofen

: Iupac Name：4-amino-3-(4-chlorophenyl)butanoic acid; CAS No.: 1134-47-0; Molecular Weight：213.661; Modify Date.: 2022-11-05 04:33; Introduction: Odorless or practically odorless white to off-white crystalline powder. View more+

Request For Quotation

1. Names and Identifiers

: 1.1 Name; Baclofen; 1.2 Synonyms; (±)-Baclofen (±)-Β-(Aminomethyl)-4-chlorobenzenepropanoic acid (R,S)-Baclofen 4-Amino-3-(4-chlorophenyl)butanoic acid 4-Amino-3-(4-chlorophenyl)butyric Acid 4-Amino-3-(p-chlorophenyl)butyric acid Atrofen b-(Aminomethyl)-4-chlorobenzenepropanoic Acid b-(Aminomethyl)-p-chlorohydrocinnamic Acid baclon benzenepropanoic acid, b-(aminomethyl)-4-chloro- Benzenepropanoic acid, β-(aminomethyl)-4-chloro- Benzenepropanoic acid, Β-(aminomethyl)-4-chloro-(9CI) Benzenepropanoic acid, Β-(aminomethyl)-4-chloro-, (±)- CIBA Ba 34647 Clofen DL-4-Amino-3-p-chlorophenylbutanoic acid DL-Baclofen EINECS 214-486-9 Hydrocinnamic acid, Β-(aminomethyl)-p-chloro- Hydrocinnamic acid, β-(aminomethyl)-p-chloro- (7CI, 8CI) Lioresa Lioresal MFCD00055143 Z1YR DG&1VQKemstro β-(4-Chlorophenyl)-γ-aminobutyric acid β-p-Chlorophenyl-GABA; View all

1.3 CAS No.: 1134-47-0

1.4 CID: 2284

1.5 EINECS(EC#): 214-486-9

1.6 Molecular Formula: C10H12ClNO2 (isomer)

1.7 Inchi: InChI=1S/C10H12ClNO2/c11-9-3-1-7(2-4-9)8(6-12)5-10(13)14/h1-4,8H,5-6,12H2,(H,13,14)

1.8 InChIkey: KPYSYYIEGFHWSV-UHFFFAOYSA-N

1.9 Canonical Smiles: C1=CC(=CC=C1C(CC(=O)O)CN)Cl

1.10 Isomers Smiles: C1=CC(=CC=C1C(CC(=O)O)CN)Cl

2. Properties

2.1 Density: 1.285

2.1 Melting point: 208-210oC

2.1 Boiling point: 364.3oC at 760 mmHg

2.1 Refractive index: 1.576

2.1 Flash Point: 174.1oC

2.1 Precise Quality: 213.05600

2.1 PSA: 63.32000

2.1 logP: 2.55730

2.1 Solubility: 1 M HCl: 50?mg/mL

2.2 Appearance: white to very faintly yellow solid

2.3 Storage: Keep Cold.

2.4 Color/Form: Powder

2.5 Physical: PHYSICAL DESCRIPTION: Odorless or practically odorless white to off-white crystalline powder. (NTP, 1992)

2.6 pKa: pKa 3.87±0.1(H2O) (Uncertain)

2.7 Water Solubility: 1 M HCl: 50?mg/mL

2.8 StorageTemp: 2-8°C

3. Use and Manufacturing

3.1 Definition: ChEBI: A monocarboxylic acid that is butanoic acid substituted by an amino group at position 4 and a 4-chlorophenyl group at position 3. It acts as a central nervous system depressant, GABA agonist and muscle relaxant.

3.2 General Description: Odorless or practically odorless white to off-white crystalline powder.

3.3 GHS Classification: Signal: Danger
GHS Hazard Statements
Aggregated GHS information provided by 39 companies from 9 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

H301 (87.18%): Toxic if swallowed [Danger Acute toxicity, oral]
H302 (12.82%): Harmful if swallowed [Warning Acute toxicity, oral]
H315 (71.79%): Causes skin irritation [Warning Skin corrosion/irritation]
H317 (69.23%): May cause an allergic skin reaction [Warning Sensitization, Skin]
H319 (71.79%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]
H334 (69.23%): May cause allergy or asthma symptoms or breathing difficulties if inhaled [Danger Sensitization, respiratory]
H335 (69.23%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure; Respiratory tract irritation]
H336 (12.82%): May cause drowsiness or dizziness [Warning Specific target organ toxicity, single exposure; Narcotic effects]
H360 (61.54%): May damage fertility or the unborn child [Danger Reproductive toxicity]
H361 (17.95%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]

Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.

Precautionary Statement Codes
P201, P202, P261, P264, P270, P271, P272, P280, P281, P285, P301+P310, P301+P312, P302+P352, P304+P340, P304+P341, P305+P351+P338, P308+P313, P312, P321, P330, P332+P313, P333+P313, P337+P313, P342+P311, P362, P363, P403+P233, P405, and P501; View all

3.4 Usage: 1. The product is a relaxant and antispasmodic agent acting on the skeletal muscle of spinal cord. Suitable for treating multiple-sclerosis bones spasms, spinal infection, degenerated muscle spasms; spinal cord trauma, and neoplastic muscle spasms.2. It is currently the most effective muscle relaxants with least side effects.

4. Safety and Handling

4.1 Symbol: GHS06;GHS08;

4.1 Hazard Codes: T

4.1 Signal Word: DANGER

4.1 Risk Statements: R61;R25;R36/37/38;R42/43

4.1 Safety Statements: S52;S22;S36/37/39;S45

4.1 Packing Group: III

4.1 Fire Hazard: Flash point data for Baclofen are not available. Baclofen is probably combustible.

4.2 Hazard Class: 6.1(b)

4.2 Hazard Declaration: H301; H315; H317; H319; H334; H335; H360

4.2 RIDADR: UN 2811

4.2 Safety Profile: Poison by ingestion,subcutaneous and intravenous routes. Human systemiceffects by ingestion: blood pressure lowering, coma,muscle weakness, pulse rate decrease, respiratorydepression. When heated to decomposition it emits toxicfumes of Cl-

4.3 Caution Statement: Missing Phrase - N15.00950417-P201-P261-P280-P284-P308 + P313

4.3 WGK Germany: 3

4.3 RTECS: MW5084200

4.3 Safety: Poison by ingestion, subcutaneous and intravenous routes. Human systemic effects by ingestion: blood pressure lowering, coma, muscle weakness, pulse rate decrease, respiratory depression. When heated to decomposition it emits toxic fumes of Cl⁻ and NO_x. A muscle relaxant.
Safety Information of Baclofen (CAS NO.1134-47-0)
Hazard Codes: T,Xn
Risk Statements: 61-25-36/37/38-42/43-20/21/22
R61:May cause harm to the unborn child.
R25 :Toxic if swallowed.
R36/37/38:Irritating to eyes, respiratory system and skin.
R42/43:May cause sensitization by inhalation and skin contact.
R20/21/22:Harmful by inhalation, in contact with skin and if swallowed.
Safety Statements: 53-22-36/37/39-45-52-26
S53:Avoid exposure - obtain special instructions before use.
S22:Do not breathe dust.
S36/37/39:Wear suitable protective clothing, gloves and eye/face protection.
S45:In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
S52:Not recommended for interior use on large surface areas.
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
RIDADR: UN 2811 6.1/PG 3
WGK Germany: 3
RTECS: MW5084200
HazardClass: 6.1(b)
PackingGroup: III; View all

4.4 Toxicity

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
man	TDLo	oral	571ug/kg (0.571mg/kg)	LUNGS, THORAX, OR RESPIRATION: DYSPNEA	Annals of Pharmacotherpy. Vol. 27, Pg. 883, 1993.
man	TDLo	oral	4286ug/kg (4.286mg/kg)	BEHAVIORAL: COMA CARDIAC: PULSE RATE VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION	American Journal of Emergency Medicine. Vol. 4, Pg. 552, 1986.
man	TDLo	oral	14mg/kg (14mg/kg)	BEHAVIORAL: MUSCLE WEAKNESS BEHAVIORAL: COMA	Journal of Toxicology, Clinical Toxicology. Vol. 20, Pg. 59, 1983.
man	TDLo	oral	3429mg/kg (3429mg/kg)	BEHAVIORAL: COMA CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP LUNGS, THORAX, OR RESPIRATION: RESPIRATORY OBSTRUCTION	Journal of Toxicology, Clinical Toxicology. Vol. 32, Pg. 291, 1994.
man	TDLo	unreported	857ug/kg/2D-I (0.857mg/kg)	BRAIN AND COVERINGS: CHANGES IN SURFACE EEG BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS"	Italian Journal of Neurological Sciences. Vol. 12, Pg. 323, 1991.
mouse	LD50	intravenous	31mg/kg (31mg/kg)	BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: ATAXIA LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION	Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 21, Pg. 2069, 1979.
mouse	LD50	oral	200mg/kg (200mg/kg)		Drugs in Japan Vol. 6, Pg. 576, 1982.
mouse	LD50	subcutaneous	103mg/kg (103mg/kg)		Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 11, Pg. 181, 1980.
rat	LD50	intravenous	78mg/kg (78mg/kg)		Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 11, Pg. 181, 1980.
rat	LD50	oral	145mg/kg (145mg/kg)		Drugs in Japan Vol. 6, Pg. 576, 1982.
rat	LD50	subcutaneous	115mg/kg (115mg/kg)		Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 11, Pg. 181, 1980.
women	TDLo	oral	8mg/kg (8mg/kg)	CARDIAC: PULSE RATE LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION	Postgraduate Medical Journal. Vol. 57, Pg. 580, 1981.
women	TDLo	oral	9mg/kg (9mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: COMA LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES	Postgraduate Medical Journal. Vol. 56, Pg. 865, 1980.
women	TDLo	oral	18mg/kg (18mg/kg)	BEHAVIORAL: COMA LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION	Journal of Toxicology, Clinical Toxicology. Vol. 22, Pg. 11, 1984.
women	TDLo	parenteral	25ug/kg/2D-I (0.025mg/kg)	SENSE ORGANS AND SPECIAL SENSES: MYDRIASIS (PUPILLARY DILATION): EYE BEHAVIORAL: COMA	International Journal of Clinical Pharmacology, Therapy and Toxicology. Vol. 29, Pg. 274, 1991.

View all

5. MSDS

2.Hazard identification

2.1 Classification of the substance or mixture

Acute toxicity - Oral, Category 3

Skin irritation, Category 2

Skin sensitization, Category 1

Eye irritation, Category 2

Respiratory sensitization, Category 1

Specific target organ toxicity \u2013 single exposure, Category 3

Reproductive toxicity, Category 1B

2.2 GHS label elements, including precautionary statements

Pictogram(s)
Signal word	Danger
Hazard statement(s)	H301 Toxic if swallowed H315 Causes skin irritation H317 May cause an allergic skin reaction H319 Causes serious eye irritation H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled H335 May cause respiratory irritation H360 May damage fertility or the unborn child
Precautionary statement(s)
Prevention	P264 Wash ... thoroughly after handling. P270 Do not eat, drink or smoke when using this product. P280 Wear protective gloves/protective clothing/eye protection/face protection. P261 Avoid breathing dust/fume/gas/mist/vapours/spray. P272 Contaminated work clothing should not be allowed out of the workplace. P284 [In case of inadequate ventilation] wear respiratory protection. P271 Use only outdoors or in a well-ventilated area. P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood.
Response	P301+P310 IF SWALLOWED: Immediately call a POISON CENTER/doctor/\u2026 P321 Specific treatment (see ... on this label). P330 Rinse mouth. P302+P352 IF ON SKIN: Wash with plenty of water/... P332+P313 If skin irritation occurs: Get medical advice/attention. P362+P364 Take off contaminated clothing and wash it before reuse. P333+P313 If skin irritation or rash occurs: Get medical advice/attention. P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P337+P313 If eye irritation persists: Get medical advice/attention. P304+P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing. P342+P311 If experiencing respiratory symptoms: Call a POISON CENTER/doctor/... P312 Call a POISON CENTER/doctor/\u2026if you feel unwell. P308+P313 IF exposed or concerned: Get medical advice/ attention.
Storage	P405 Store locked up. P403+P233 Store in a well-ventilated place. Keep container tightly closed.
Disposal	P501 Dispose of contents/container to ...

2.3 Other hazards which do not result in classification

none

View all

6. NMR Spectrum

13C NMR : Predict

1H NMR : Predict

Predict 1H proton NMR

Mass spectrum (electron ionization)

7. Synthesis Route

1134-47-0Total: 9 Synthesis Route

99-91-2 190 Suppliers

1134-47-0 276 Suppliers

Literatures:
Australian Journal of Chemistry, , vol. 34, # 12 p. 2641 - 2645
Yield: null

1679-18-1 341 Suppliers

1134-47-0 276 Suppliers

Literatures:
RSC Advances, , vol. 4, # 5 p. 2538 - 2545
Yield: null

22518-27-0 13 Suppliers

1134-47-0 276 Suppliers

Literatures:
Biswas, Kallolmay; Gholap, Rajesh; Srinivas, Padakanti; Kanyal, Sachin; Sarma, Koushik Das RSC Advances, 2014 , vol. 4, # 5 p. 2538 - 2545
Yield: ~81%

View all

8. Precursor and Product

precursor:

81187-89-5

81187-91-9

1679-18-1

99-91-2

81187-90-8

81187-93-1

21133-98-2

927207-26-9

22518-27-0

product :

120418-62-4

229014-55-5

22518-27-0

9. Other Information

9.0 Merck: 14,937

9.1 Production process: Chlorobenzaldehyde and ethyl acetoacetate are condensed into chlorobenzene methylene-bis-ethyl acetoacetate. Heat and hydrolyze to obtain chlorophenyl glutaric acid. Use acetic anhydride for dehydration and cyclization to obtain chlorophenyl glutaric anhydride. And then perform amination reaction by concentrated aqueous ammonia to generate chlorophenyl glutaric acid imide. The open the ring, degrade to obtain the final product.

9.2 Pharmacokinetics: After oral administration, concentration in plasma reaches a peak in about 1.9h. There is large fluctuation in plasma concentration with the maximum concentration/minimum concentration × 100%: 188-439%. The total clearance rate is about 175mL.min-1, and the apparent renal clearance crisp is the same as that of muscle. The plasma protein binding rate is 35%. The excretion rate of kidney prototype drug is 65%, which is consistent with healthy results. Because renal excretion is the major route of elimination, patients with renal impairment should pay attention to adjust the dose.

9.3 Indications: This product is an antispasmodic drug. It inhibits the transmission in spinal cord of mono-synapse multiple synapse. The mechanism is inhibiting the release of excitatory amino acid glutamate and aspartate through stimulating GABA receptor. Thus reduce the increased limbs muscle tension caused by spinal cord lesions, multiple sclerosis, and spinal cord injury. It can be used for treatment of muscle spasms caused by brain and spinal cord diseases or injuries.

9.4 Precautions: 1. Among the overdose behavior, the depression of central nervous system is the most prominent. Severe poisoning manifestations include seizures, coma, respiratory depression and muscle hypotonia associated with loss of reflexes of the limbs, and also hypotension and low blood pressure sometimes. Strategies for emergence treatment of acute poisoning include respiratory support, gastric lavage, and diuretic. However, there is no special antidote reported. There are some reports that seizures and myoclonic seizures appeared in some patients appear during the recovery period. Epileptic seizure can be treated by diazepam or clonazepam, although these drugs can cause extension of the duration of unconsciousness. Patients of cardiovascular disease should be carefully observed for 1 week to monitor delayed tachycardia and hypertension.
2. Patients who are allergic to the drug, suffering Parkinson's disease, spasms, and the women who are in the first three months of pregnancy are not allowed for using.
3. Patients of hypertension, peptic ulcer disease, cerebrovascular disease and respiratory, issue liver and kidney dysfunction, who have a history of seizures or convulsions, accompanied by mental disorders, schizophrenia or confusion, pregnant and lactating women, drivers or operator of machine should use with caution.
4. Epileptic patients should be controlled of the attack of epilepsy when applying this drug. Also they should do EEG monitoring.
5. Gradually reduce the dosage before the withdrawal, to prevent rebound phenomenon.; View all

9.5 Side effects: The main side effects mainly happen at the beginning of treatment when the dose increases too fast, when overdose happens and for elderly patients. It is mainly mild transient symptoms, Patients with historical mental illness and elderly patients with cerebral vascular disease may suffer from an even more severe adverse reaction. During the beginning of treatment, there are often some side effects such as daytime sedation, drowsiness and nausea.

9.6 Dosage and usage: Oral: adult, Initial amount of 5mg per time, tid, then every increase taking this amount every 3d until it reaches the appropriate dose 30~75mg/d. Take this in 3 times. The dose should not exceed 80 mg/d except in special cases. Gradually reduce the dosage before withdrawal; For children, the initial amount should be 0.3mg/(kg.d), and the maintenance dose should be 0.75~2mg/(kg.d). For children under 10 years-old, the maximum dose should be 2.5mg /(kg.d). The recommended daily amount for maintenance therapy: 1 to 2 years-old, 10~20mg, 2~10 years-old: 30~60mg (maximum 70mg), take it with meal or with milk.

9.7 Chemical Properties: White powder. Melting point: 206-208 °C. Dissolve using hot water, the aqueous solution was neutral, almost insoluble in alcohol, ether, acetone and other organic solvents, easily soluble in acidic, alkaline aqueous solution. The melting point of Chlorobenzene aminobutyric acid hydrochloride: 179-181 °C.

9.8 Uses: 1. The product is a relaxant and antispasmodic agent acting on the skeletal muscle of spinal cord. Suitable for treating multiple-sclerosis bones spasms, spinal infection, degenerated muscle spasms; spinal cord trauma, and neoplastic muscle spasms.
2. It is currently the most effective muscle relaxants with least side effects.

9.9 Category: toxic substances

9.10 Toxicity grading: highly toxic

9.11 Acute toxicity: Oral-rat LD50; 145 mg/kg; Oral-Mouse LD50: 200 mg/kg.

9.12 Flammability and hazardous characteristics: Combustible, Burning yields toxic chloride fumes and nitrogen oxides; Patients takes with side effects: low blood pressure, pulse rate decreases, muscle weakness.

9.13 Chemical Properties: Off-White Solid

9.14 Storage Characteristics: ventilation, low-temperature and dry; and Separate from food raw materials for storage.

9.15 Uses: Specific GABA-B receptor agonist. Muscle relaxant (skeletal)

9.16 Definition: ChEBI: A monocarboxylic acid that is butanoic acid substituted by an amino group at position 4 and a 4-chlorophenyl group at position 3. It acts as a central nervous system depressant, GABA agonist and muscle relaxant.

9.17 Brand name: Kemstro (Schwarz Pharma); Lioresal (Medtronic); Lioresal (Novartis).

9.18 Extinguishing agent: Dry powder, foam, sand, carbon dioxide, water spray.

9.19 General Description: Odorless or practically odorless white to off-white crystalline powder.

9.20 Air & Water Reactions: Insoluble in water.

9.21 Reactivity Profile: Baclofen is an amine. Amines are chemical bases. They neutralize acids to form salts plus water. These acid-base reactions are exothermic. The amount of heat that is evolved per mole of amine in a neutralization is largely independent of the strength of the amine as a base. Amines may be incompatible with isocyanates, halogenated organics, peroxides, phenols (acidic), epoxides, anhydrides, and acid halides. Flammable gaseous hydrogen is generated by amines in combination with strong reducing agents, such as hydrides.

9.22 Health Hazard: SYMPTOMS: Symptoms of exposure to Baclofen via ingestion may include drowsiness, insomnia, dizziness, weakness, mental confusion, nausea, constipation, anorexia, urinary retention, impotence, nystagmus, diplopia and incoordination. Ingestion may lead to cholinergic effects and lassitude. It may also lead to ataxia. Other symptoms due to ingestion may include impaired renal function, fatigue, headache, hypotension, urinary frequency, rash, pruritis, ankle edema, excessive perspiration, weight gain, nasal congestion, and rarely, euphoria, excitement, depression, hallucinations, paresthesia, muscle pain, tinnitus, slurred speech, tremor, rigidity, dystonia, blurred vision, strabismus, miosis, mydriasis, dysarthia, epileptic seizure, dyspnea, palpitation, chest pain, syncope, dryness of the mouth, taste disorder, abdominal pain, vomiting, diarrhea, blood in the stools, enuresis, dysuria, inability to ejaculate, nocturia and hematuria. Overexposure through ingestion may result in seizures, and coma with respiratory depression. Aspiration pneumonia is a frequent complication of coma with respiratory depression. Other symptoms due to overdosage may include vomiting, muscular hypotonia, drowsiness, and accommodation disorders. Cyanosis has been reported. Chronic ingestion may result in drowsiness, depression, weakness, anxiety, ataxia, headaches, blurred vision, gastric upset and pruritic skin rashes characterized by urticaria or erythematous macular eruptions. Sudden withdrawal after chronic ingestion may cause auditory and visual hallucinations, anxiety and tachycardia. Seizures may also occur after sudden withdrawal. Abuse may lead to drug dependence.; View all

9.23 Fire Hazard: Flash point data for Baclofen are not available. Baclofen is probably combustible.

9.24 Biological Activity: Selective GABA B receptor agonist. Skeletal muscle relaxant.

9.25 Usage: Selective GABA-b receptor agonist

10. Computational chemical data

Molecular Weight: 213.661g/mol
Molecular Formula: C₁₀H₁₂ClNO₂
Compound Is Canonicalized: True
XLogP3-AA: null
Exact Mass: 213.0556563
Monoisotopic Mass: 213.0556563
Complexity: 191
Rotatable Bond Count: 4
Hydrogen Bond Donor Count: 2
Hydrogen Bond Acceptor Count: 3
Topological Polar Surface Area: 63.3
Heavy Atom Count: 14
Defined Atom Stereocenter Count: 0
Undefined Atom Stereocenter Count: 1
Defined Bond Stereocenter Count: 0
Undefined Bond Stereocenter Count: 0
Isotope Atom Count: 0
Covalently-Bonded Unit Count: 1
CACTVS Substructure Key Fingerprint: AAADccByMAAEAAAAAAAAAAAAAAAAAAAAAAAwAAAAAAAAAAABAAAAHgIQCAAADQLBmCQwCIBAAgCIAiDSCAACAAAgBQAIiIEAAogIIDKBkxGAYAAkkAAIiAe8yOCOhAAAAAAAAAAIAAAAAAAAAAAAAAAAAA==

11. Question & Answer

How is Baclofen extracted and prepared? Aug 23 2023
Baclofen is a commonly used pharmaceutical ingredient with a wide range of applications in the medical field. So, how is Baclofen extracted and prepared? The extraction and preparation process of Bacl..
What is Baclofen and how does it work? Mar 26 2023
Baclofen is a muscle relaxant for skeletal muscles used to treat muscle spasms, spinal cord injuries, or multiple sclerosis. It was approved for medical use in the United States in 1977 and can be use..
How to Store Baclofen and Ensure Its Effectiveness Nov 11 2021
Baclofen is a medication used to treat various conditions such as spinal cord tumors, multiple sclerosis, meningitis, and skeletal muscle spasms caused by cerebrovascular disease or head trauma. It h..

12. Recommended Suppliers

Global269SuppliersView all >>

Hebei Chengcai Biotechnology Co., LTD Diamond member

1YR

Products:We are engaged in the development, marketing and sales of apis, intermediates, natural products (extracts), fine chemicals, food additives, agricultural chemicals and other products.
Tel:0086-0319-19131200228
Email:17610795226@chengcaibio.com

Baclofen CAS 1134-47-0 for API.

Purity:99%Packing: 200kg/bag FOB
Price: 1 USD/kg
Time: 2023/10/03

Inquire

Hebei Crovell Biotech Co. Ltd Diamond member

3YRS

Products:Cosmetic Raw Materials,solvents,etc.
Tel:86-311-66562153
Email:breeduan@crovellbio.com

Factory supply baclofen Cas 1134-47-0 from China

Purity:99%Packing: 200kg/bag FOB
Price: 10 USD/kilogram
Time: 2023/09/28

Inquire

Xiamen wonderful Biotechnology Co., Ltd. Diamond member

1YR

Products:Top quality and high purity with safe transportation and low price
Tel:+86131-10924135-13110924135
Email:Cici@xmwonderfulbio.com

Baclofen

Purity:99%Packing: 200kg/bag FOB
Price: 1 USD/kg
Time: 2023/09/28

Inquire

Jiangsu Kaihuida New Material Technology Co., Ltd Diamond member

1YR

Products:Pharmaceutical intermediates,Food additive,Organic intermediate,Cosmetic materials,Chemical Raw materials,Plant Growth Regulator and other products.
Tel:86-516-13179737552
Email:emily@jskaihuida.com

Factory Supply 99% Purity Powder Baclofen CAS1134-47-0